Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goeckerman therapy in psoriasis vulgaris
NCT03662685Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- Aug 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Tarsum in Psoriasis vulgaris (PV), sponsored by University of California, San Francisco. Primary endpoint: Number of differentially expressed immune cell populations at 12 weeks. Started Aug 2018; status: terminated.
02
Drugs
Tarsum
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT03662685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662685.